News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

The Michael J. Fox Foundation Announces Award to Drive Phase IIa Clinical Trial Investigating Potential Safety and Benefit of Nilotinib in PD

(July 28, 2017) - The Michael J. Fox Foundation for Parkinson's Research today announced U.S. Food and Drug Administration (FDA) approval of a multicenter, double-blind, randomized, placebo-controlled Phase IIa clinical trial to test safety and tolerability of nilotinib (Tasigna) in Parkinson's disease (PD). The trial is designed to investigate the potential of repurposing nilotinib, an FDA-approved treatment for chronic myelogenous leukemia, for use in Parkinson's disease. Read more